News Sentiment

INKT sentiment intelligence

Mink Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 54 Balanced news tone 60 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 10.66 Week of 17 Jul 2026
Weighted tone 54/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

82/100 classification confidence.

Company focus 51

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

-3.5% over one week, -12.2% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Positive

Here's Why You Should Add INKT Stock to Your Portfolio Now

Market Reaction

Balanced read

64/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 82/100 classification
One-week reaction -3.5% Price reacting lower
Trend fit Trend inactive -12.2% over four weeks
Fair value -1.2% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 12
Neutral 45
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 51
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
TradingView 11
Market source 8
marketscreener.com 5
GlobeNewswire 5
Quartr 4
Stock Traders Daily 3
Investing.com 3
simplywall.st 3

Event Lens

What the news is about

Classified themes
Market update 36
Earnings 19
Regulatory and legal 2
Balance sheet 2
Analyst action 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 60
TradingView Direct company coverage

Here's Why You Should Add INKT Stock to Your Portfolio Now

MiNK Therapeutics (INKT) is a biotechnology company focused on developing allogeneic invariant natural killer T (iNKT) cell therapies for various life-threatening diseases, including oncology and respiratory conditions. The company's lead candidate, agenT-797, is showing promisin

Tone
Positive 70/100
Event
Market update
Published
16 Jul 2026 16:41
Source
TradingView
Stock Traders Daily Direct company coverage

Why (INKT) Price Action Is Critical for Tactical Trading

This article analyzes Mink Therapeutics Inc. (NASDAQ: INKT) with a focus on its price action for tactical trading, identifying weak sentiment across all horizons and supporting a short bias. It details an exceptional risk-reward setup targeting a 54.4% gain versus 0.3% risk, and

Tone
Negative 30/100
Event
Market update
Published
13 Jul 2026 23:40
Source
Stock Traders Daily
Quartr Direct company coverage

Mink Therapeutics (INKT) Proxy filing Summary

Mink Therapeutics (INKT) has released a proxy filing summary ahead of its Annual Meeting on June 17, 2026. The meeting will address the election of three Class II directors and the ratification of KPMG LLP as the independent registered public accounting firm. Stockholders as of A

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 23:09
Source
Quartr
Quartr Direct company coverage

Mink Therapeutics (INKT) H.C. Wainwright 26th Annual Global Investment Conference 2024 summary

Mink Therapeutics presented a summary of their pipeline and development status at the H.C. Wainwright 26th Annual Global Investment Conference 2024. The company focuses on off-the-shelf invariant natural killer T (iNKT) cell therapies, with their lead program agenT-797 in Phase I

Tone
Positive 71/100
Event
Market update
Published
10 Jul 2026 19:09
Source
Quartr
Quartr Direct company coverage

Mink Therapeutics (INKT) Q1 2025 earnings summary

Mink Therapeutics (INKT) announced Q1 2025 financial results, reporting a net loss of $2.8 million and a cash balance of $3.2 million. The company achieved significant clinical milestones in cancer therapy and secured probable NIAID funding for its GVHD program, expecting to pres

Tone
Neutral 50/100
Event
Earnings
Published
09 Jul 2026 04:40
Source
Quartr
TradingView Direct company coverage

Cost of goods sold of MiNK Therapeutics, Inc. – DUS:6Q40

This article focuses on the "Cost of goods sold" for MiNK Therapeutics, Inc., specifically for its listing on the Dusseldorf Stock Exchange under the ticker 6Q40. The content is presented as a financial data point within the broader context of the company's financial overview on

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 05:39
Source
TradingView
Stock Traders Daily Direct company coverage

Understanding Momentum Shifts in (INKT)

This article provides an in-depth analysis of Mink Therapeutics Inc. (NASDAQ: INKT) utilizing AI models to identify momentum shifts and suggest trading strategies. It highlights a near-term weak sentiment that may lead to a resumption of long-term weakness after a neutral shift,

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 22:32
Source
Stock Traders Daily
www.marketscreener.com Direct company coverage

MiNK Therapeutics, Inc.(NasdaqCM:INKT) added to Russell Microcap Value Benchmark Index

MiNK Therapeutics, Inc. (NasdaqCM:INKT) has been added to the Russell Microcap Value Benchmark Index, as reported on June 29, 2026. This inclusion signifies the company's recognition within the microcap investment community. The clinical-stage biopharmaceutical company focuses on

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 16:32
Source
www.marketscreener.com
marketscreener.com Direct company coverage

MiNK Therapeutics, Inc.(NasdaqCM:INKT) added to Russell 3000E Value Benchmark

MiNK Therapeutics, Inc. (NasdaqCM: INKT) has been added to the Russell 3000E Value Benchmark Index. This inclusion highlights the company's growing presence in the financial markets and follows several other recent inclusions in various Russell Microcap and 3000E indices. MiNK Th

Tone
Positive 72/100
Event
Market update
Published
29 Jun 2026 15:40
Source
marketscreener.com
marketscreener.com Direct company coverage

MiNK Therapeutics, Inc.(NasdaqCM:INKT) added to Russell Microcap Growth Benchmark Index

MiNK Therapeutics, Inc. (NasdaqCM: INKT) has been added to the Russell Microcap Growth Benchmark Index. This inclusion means the company's stock will now be tracked by this widely recognized index, potentially increasing its visibility and attractiveness to growth-focused investo

Tone
Positive 74/100
Event
Market update
Published
29 Jun 2026 12:28
Source
marketscreener.com
marketscreener.com Direct company coverage

MiNK Therapeutics, Inc.(NasdaqCM:INKT) added to Russell Microcap Index

MiNK Therapeutics, Inc. (NasdaqCM: INKT), a clinical-stage biopharmaceutical company focused on allogeneic invariant natural killer T (iNKT) cell therapies, has been added to the Russell Microcap Index. This inclusion follows several recent developments for the company, including

Tone
Positive 67/100
Event
Market update
Published
29 Jun 2026 05:41
Source
marketscreener.com
www.marketscreener.com Direct company coverage

MiNK Therapeutics, Inc.(NasdaqCM:INKT) added to Russell 3000E Growth Benchmark

MiNK Therapeutics, Inc. (NasdaqCM: INKT) has been added to the Russell 3000E Growth Benchmark. This inclusion follows previous additions to the Russell Microcap Value and Microcap Growth Benchmark Indexes. MiNK Therapeutics is a clinical-stage biopharmaceutical company focused on

Tone
Positive 72/100
Event
Market update
Published
29 Jun 2026 04:46
Source
www.marketscreener.com
TradingView Direct company coverage

INKT Forecast — Price Target — Prediction for 2027

This article provides a forecast for MiNK Therapeutics, Inc. (INKT) stock, including analyst price targets and a prediction for 2027. It details the current stock price, historical performance, market capitalization, and upcoming earnings report. The piece also addresses frequent

Tone
Neutral 50/100
Event
Analyst action
Published
28 Jun 2026 07:41
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBITDA forward of MiNK Therapeutics, Inc. – NASDAQ:INKT

The article provides financial data for MiNK Therapeutics, Inc. (NASDAQ: INKT), focusing on its enterprise value to EBITDA forward. It indicates the stock is listed on the Nasdaq Stock Market and that the market was closed at the time of publication, with no trades observed.

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 16:10
Source
TradingView
TradingView Direct company coverage

MiNK Therapeutics, Inc. Actuals & Estimates (NASDAQ:INKT)

This article provides an overview of MiNK Therapeutics, Inc. (NASDAQ:INKT) stock, including its current price, historical performance, analyst forecasts, and financial data. It highlights the company's market capitalization, upcoming earnings date, and past earnings and revenue f

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 09:10
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of MiNK Therapeutics, Inc. – NASDAQ:INKT

The article focuses on the "Price to earnings forward" financial metric for MiNK Therapeutics, Inc. (NASDAQ: INKT). It provides a snapshot of this financial data on the TradingView platform, noting that the market was closed with no trades at the time of viewing.

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 09:09
Source
TradingView
Simply Wall Street Direct company coverage

MiNK Therapeutics (Nasdaq:INKT) - Stock Analysis

MiNK Therapeutics (Nasdaq:INKT) is a clinical-stage biopharmaceutical company focused on allogeneic, off-the-shelf iNKT cell therapies for cancer and immune-mediated diseases. The company is currently trading significantly below its estimated fair value and faces risks including

Tone
Positive 63/100
Event
Market update
Published
24 Jun 2026 23:10
Source
Simply Wall Street
Investing.com Nigeria Direct company coverage

Form 8K Mink Therapeutics Inc For: 23 June By Investing.com

This article reports that Mink Therapeutics Inc. filed a Form 8K on June 23, 2026. This filing is a standard requirement for significant events that shareholders should be aware of. The article also provides current market data for various indices, commodities, bonds, and shares,

Tone
Neutral 50/100
Event
Market update
Published
24 Jun 2026 10:41
Source
Investing.com Nigeria
TradingView Direct company coverage

Total liabilities & shareholders' equities of MiNK Therapeutics, Inc. – DUS:6Q40

This article provides financial data on total liabilities and shareholders' equities for MiNK Therapeutics, Inc. (DUS:6Q40) as listed on the Dusseldorf Stock Exchange. It highlights the availability of this specific financial metric from TradingView, which sources its data from I

Tone
Neutral 50/100
Event
Market update
Published
23 Jun 2026 19:10
Source
TradingView
Stock Titan Direct company coverage

MiNK Therapeutics (INKT) investors reelect board members and ratify KPMG at 2026 meeting

MiNK Therapeutics, Inc. held its Annual Meeting of Stockholders on June 17, 2026, where investors reelected Garo Armen, Barbara Ryan, and John Holcomb as Class II directors for three-year terms. Additionally, stockholders ratified the appointment of KPMG LLP as the independent re

Tone
Neutral 50/100
Event
Market update
Published
23 Jun 2026 14:10
Source
Stock Titan
Quartr Direct company coverage

Mink Therapeutics (INKT) AGM 2026 Summary

The Mink Therapeutics (INKT) Annual General Meeting (AGM) 2026 summary details the formal proceedings, including the appointment of an Inspector of Elections and the establishment of a quorum. Key voting outcomes included the approval of three Class II directors for three-year te

Tone
Neutral 50/100
Event
Regulatory and legal
Published
22 Jun 2026 21:11
Source
Quartr
Stock Traders Daily Direct company coverage

Avoiding Lag: Real-Time Signals in (INKT) Movement

The article analyzes Mink Therapeutics Inc. (NASDAQ: INKT), highlighting mixed sentiment leading to choppy conditions. It reveals an exceptional 295.0:1 risk-reward setup, targeting a 93.5% gain, and outlines specific trading strategies (Position, Momentum Breakout, Risk Hedging)

Tone
Positive 71/100
Event
Market update
Published
21 Jun 2026 21:20
Source
Stock Traders Daily
TradingView Direct company coverage

Inventory turnover of MiNK Therapeutics, Inc. – DUS:6Q40

The article discusses the inventory turnover of MiNK Therapeutics, Inc. (DUS: 6Q40) on the Dusseldorf Stock Exchange. It provides general financial information about the company's stock activity, noting that the market is currently closed with no trades. The content primarily foc

Tone
Neutral 50/100
Event
Market update
Published
21 Jun 2026 16:10
Source
TradingView
TradingView Direct company coverage

Book value per share of MiNK Therapeutics, Inc. – DUS:6Q40

This article provides financial information for MiNK Therapeutics, Inc. (DUS:6Q40), specifically focusing on its book value per share. The content is presented within the TradingView platform, noting that the market is currently closed for this stock.

Tone
Neutral 50/100
Event
Market update
Published
19 Jun 2026 15:11
Source
TradingView
TradingView Direct company coverage

MiNK Therapeutics, Inc. Cash Flow – DUS:6Q40

This article provides key cash flow figures for MiNK Therapeutics, Inc. (DUS:6Q40). It highlights that the free cash flow for Q1 2026 was -1.50M EUR, and for the full year 2025, operating cash flow and free cash flow were both -5.04M EUR. The article also presents a historical br

Tone
Negative 38/100
Event
Balance sheet
Published
19 Jun 2026 09:39
Source
TradingView
TradingKey Direct company coverage

Mink Therapeutics Inc (INKT) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for Mink Therapeutics Inc (INKT), focusing on key metrics like P/E, P/B, P/S, and P/CF ratios. It highlights that relevant data for these valuation dimensions have not yet been disclosed by the company. The page also presents current sto

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 10:09
Source
TradingKey